Bulging Eye Disease Cases Rising Among Women Over 40: Report
Thyroid Eye Disease (TED) is increasingly affecting women over 40, causing bulging eyes due to inflammation and swelling around the eyes. This autoimmune condition often occurs in people with hyperthyroidism (overactive thyroid) or Graves' disease. Common symptoms include:
Dry or Gritty Eyes: Irritation and Discomfort
Sensitivity to Light: Increased sensitivity
Ache Behind the Eyes: Pain that worsens when looking up
Bulging Eyes: Eyes protruding from the socket
Effects of Proptosis (Bulging Eyes) on Your Well-Being
According to the Cleveland Clinic, the condition can affect your appearance, leaving you with a startled expression that doesn't go away. Proptosis (Bulging Eyes) can also make it difficult for you to blink. When you can't blink, the protective outer layer of your eyes (corneas) doesn't receive the lubrication it needs to do its job. You may be at risk for cornea damage. Some people experience other complications, like low vision or double vision (diplopia). Other names for proptosis include bulging eyes, protruding eyes and exophthalmos.
TED affects approximately 50,000 people in the UK, with women being five times more likely to develop the condition than men. If left untreated, TED can lead to sight loss and have a devastating impact on mental health. Treatment options include steroids, lubricating eye drops, and surgery. Researchers are exploring new treatments, such as targeted drugs acting on the immune system. Early diagnosis and treatment are crucial to managing symptoms and preventing long-term damage.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
15 hours ago
- The Hindu
New ‘weight-loss' drugs have lower impact in real life compared to clinical trial results: study
A recent study done in the U.S. showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, than during the clinical trial, because patients discontinue treatment or use lower maintenance dosages. The results were published by researchers from the Cleveland Clinic, Ohio, U.S., in the peer-reviewed journal Obesity on June 10. Semaglutide and tirzepatide are FDA-approved medications for the treatment of type 2 diabetes and chronic weight management and are now also available in India. Hamlet Gasoyan et al accessed electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who started with injectable semaglutide or tirzepatide between 2021 and 2023. They recorded early discontinuation (within 3 months) and late discontinuation (within 3–12 months) along with weight reduction. The researchers observed that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically-meaningful weight reduction in patients on these drugs. Researchers also identified the factors associated with higher odds of achieving a weight loss of 10% or more, after one year of treatment — continuing medications or discontinuing late (vs. early), taking a high maintenance dosage, getting tirzepatide (vs. semaglutide) and were female (vs. male). Commenting on the results of the study, V. Mohan, senior diabetologist, and chairman, Dr. Mohan's Diabetes Specialties Centre, Chennai, who has initiated patients on weight-loss drugs, says: 'The findings are not surprising because in a randomised clinical trial (RCT), there is constant follow up with the participants to continue with the drug regimen. On the other hand, in the real world, especially if patients buy their own medication, they often stop the drug. Even otherwise, compliance rates in real world are much poorer than in an RCT. The bottom line is that these drugs work as long as they are taken. That is how it is with most drugs, if you stop statins, for instance, cholesterol levels go up; if you stop anti-diabetic drugs or BP drugs, the sugar and BP go up.' 'A reality check' Anoop Misra, who heads Fortis C-DOC Hospital for Diabetes and Allied Sciences in Delhi, who has also put his patients on these class of drugs, says: 'This study gives us a reality check of weight loss and blood sugar lowering effects of these drugs. It is important to note that discontinuation of such drugs is likely to be more in India, driven also by cost concerns. Non-compliance to diet and exercise are additional reasons to be considered in India which may cause lower weight loss.' 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' said Dr. Gasoyan.
NDTV
a day ago
- NDTV
Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
New Delhi: Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Obesity injections may have less weight loss effect in reality: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
